RT Journal Article
SR Electronic
T1 Establishment of CORONET; COVID-19 Risk in Oncology Evaluation Tool to identify cancer patients at low versus high risk of severe complications of COVID-19 infection upon presentation to hospital
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.30.20239095
DO 10.1101/2020.11.30.20239095
A1 R.J. Lee
A1 C. Zhou
A1 O. Wysocki
A1 R. Shotton
A1 A. Tivey
A1 L. Lever
A1 J. Woodcock
A1 A. Angelakas
A1 T. Aung
A1 K. Banfill
A1 M. Baxter
A1 T. Bhogal
A1 H. Boyce
A1 E. Copson
A1 E. Dickens
A1 L. Eastlake
A1 H. Frost
A1 F. Gomes
A1 D.M Graham
A1 C. Hague
A1 M. Harrison
A1 L. Horsley
A1 P. Huddar
A1 Z. Hudson
A1 S. Khan
A1 U. T. Khan
A1 A. Maynard
A1 H. McKenzie
A1 T. Robinson
A1 M. Rowe
A1 Anne Thomas
A1 Lance Turtle
A1 R. Sheehan
A1 A. Stockdale
A1 J. Weaver
A1 S. Williams
A1 C. Wilson
A1 R. Hoskins
A1 J. Stevenson
A1 P. Fitzpatrick
A1 C. Palmieri
A1 D. Landers
A1 T Cooksley
A1 C. Dive
A1 A. Freitas
A1 A. C. Armstrong
YR 2020
UL http://medrxiv.org/content/early/2020/12/03/2020.11.30.20239095.abstract
AB Background Cancer patients are at increased risk of severe COVID-19. As COVID-19 presentation and outcomes are heterogeneous in cancer patients, decision-making tools for hospital admission, severity prediction and increased monitoring for early intervention are critical.Objective To identify features of COVID-19 in cancer patients predicting severe disease and build a decision-support online tool; COVID-19 Risk in Oncology Evaluation Tool (CORONET)Method Data was obtained for consecutive patients with active cancer with laboratory confirmed COVID-19 presenting in 12 hospitals throughout the United Kingdom (UK). Univariable logistic regression was performed on pre-specified features to assess their association with admission (≥24 hours inpatient), oxygen requirement and death. Multivariable logistic regression and random forest models (RFM) were compared with patients randomly split into training and validation sets. Cost function determined cut-offs were defined for admission/death using RFM. Performance was assessed by sensitivity, specificity and Brier scores (BS). The CORONET model was then assessed in the entire cohort to build the online CORONET tool.Results Training and validation sets comprised 234 and 66 patients respectively with median age 69 (range 19-93), 54% males, 46% females, 71% vs 29% had solid and haematological cancers. The RFM, selected for further development, demonstrated superior performance over logistic regression with AUROC predicting admission (0.85 vs. 0.78) and death (0.76 vs. 0.72). C-reactive protein was the most important feature predicting COVID-19 severity. CORONET cut-offs for admission and mortality of 1.05 and 1.8 were established. In the training set, admission prediction sensitivity and specificity were 94.5% and 44.3% with BS 0.118; mortality sensitivity and specificity were 78.5% and 57.2% with BS 0.364. In the validation set, admission sensitivity and specificity were 90.7% and 42.9% with BS 0.148; mortality sensitivity and specificity were 92.3% and 45.8% with BS 0.442. In the entire cohort, the CORONET decision support tool recommended admission of 99% of patients requiring oxygen and of 99% of patients who died.Conclusions and Relevance CORONET, a decision support tool validated in hospitals throughout the UK showed promise in aiding decisions regarding admission and predicting COVID-19 severity in patients with cancer presenting to hospital. Future work will validate and refine the tool in further datasets.Competing Interest StatementR Lee speaker fees BMS and Astrazeneca, M Rowe honoraria from Astellas Pharma, speaker fees MSD and Servier. C. Wilson consultancy and speaker fees Pfizer, Amgen, Novartis, A Armstrong conference fee Merck, spouse shares in Astrazeneca. T Robinson financial support to attend educational workshops from Amgen and Daiichi-Sankyo. C Dive, outside of this scope of work, has received research funding from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck AG, Taiho Oncology, Clearbridge Biomedics, Angle PLC, Menarini Diagnostics, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Thermofisher. C Dive is on advisory boards for, and has received consultancy fees/honoraria from, AstraZeneca, Biocartis and Merck KGaA.Funding StatementRebecca Lee and Tim Robinson are supported by the National Institute for Health Research as a Clinical Lecturer. Talvinder Bhogal is supported by the National Institute for Health Research as an academic clinical fellow. Umair Khan is an MRC Clinical Training Fellow based at the University of Liverpool supported by the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the Medical Research Council (Award Ref. MR/N025989/1). C Dive C5757/A27412), the CRUK Manchester Centre Award (C5759/A25254), and is supported by the NIHR Manchester Biomedical Research Centre. Funding for COVID-19 work has been provided by The Christie Charitable fund (1049751).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:HRA and Health and Care Research Wales (HCRW) approval granted (reference 20/WA/0269)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode for the tool is available at Github (https://github.com/oskwys/CORONET). Raw data is available upon request to corresponding author, however may not include all details due to information governance regulations. https://github.com/oskwys/CORONET https://coronet.manchester.ac.uk/